1. P1030: MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF PELABRESIB (CPI-0610) AND RUXOLITINIB VS PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-NAÏVE MYELOFIBROSIS PATIENTS. (23rd June 2022) Authors: Harrison, C.; Rampal, R. K.; Gupta, V.; Verstovsek, S.; Talpaz, M.; Kiladjian, J.-J.; Mesa, R.; Kuykendall, A.; Vannucchi, A.; Palandri, F.; Grosicki, S.; Devos, T.; Jourdan, E.; Wondergem, M. J.; Al-Ali, H. K.; Buxhofer-Ausch, V.; Alvarez-Larrán, A.; Akhani, S.; Muñoz-Carerras, R.; Sheykin, Y. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 920 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P1041: IMPACT OF FEDRATINIB ON SPLEEN VOLUME AND MYELOFIBROSIS SYMPTOMS IN PATIENTS WITH SUBSTANTIAL SPLENOMEGALY: POST HOC ANALYSES FROM THE JAKARTA AND JAKARTA2 TRIALS. (23rd June 2022) Authors: Kiladjian, J.-J.; Tefferi, A.; Passamonti, F.; Vannucchi, A.; Talpaz, M.; Cervantes, F.; Harrison, C. N.; Mesa, R. A.; Mascarenhas, J.; Schaap, N.; Verstovsek, S.; Devos, T.; Rose, S.; Zhang, J.; Sy, O.; Pardanani, A. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 931 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P1361: TREATMENT OF SEVERE STEROID-REFRACTORY ACUTE GVHD WITH MESENCHYMAL STROMAL CELLS: RESULTS OF THE PHASE III RANDOMIZED DOUBLE-BLIND MULTI-CENTER HOVON-113 TRIAL. (23rd June 2022) Authors: Oosten, L.; van Pel, M.; van der Holt, B.; Bach, E.; Cross, M.; Roelofs, H.; Meij, P.; Wieles, B.; Zwaginga, J. J.; Lankester, A.; Veelken, H.; Platzbecker, U.; Sanchez-Guijo, F.; Algeri, M.; Locatelli, F.; Devos, T.; Cornelissen, J.; Niederwieser, D.; Fibbe, W. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1245 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P699: REAL-LIFE OUTCOMES OF PONATINIB TREATMENT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) OR PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL): 5-YEAR-DATA FROM A BELGIAN REGISTRY. (23rd June 2022) Authors: Devos, T.; Havelange, V.; Theunissen, K.; Meers, S.; Benghiat, F. S.; Gadisseur, A.; Vanstraelen, G.; Vellemans, H.; Bailly, B.; Granacher, N.; Lewalle, P.; De Becker, A.; Van Eygen, K.; Lejeune, M.; Janssen, M.; Triffet, A.; Vrelust, I.; Deeren, D.; Mazure, D.; Beck, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 594 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P995: MYELOID NEOPLASMS-ASSOCIATED GENE VARIANTS IN 639 PATIENTS WITH POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT. (23rd June 2022) Authors: Mora, B.; Guglielmelli, P.; Kuykendall, A.; Maffioli, M.; Rotunno, G.; Komrokji, R. S.; Palandri, F.; Kiladjian, J.-J.; Iurlo, A.; Auteri, G.; Cattaneo, D.; De Stefano, V.; Salmoiraghi, S.; Devos, T.; Cervantes, F.; Merli, M.; Campagna, A.; Benevolo, G.; Brociner, M.; Albano, F. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 885 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. S198: BET INHIBITOR PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS — JAK INHIBITOR-NAÏVE OR WITH SUBOPTIMAL RESPONSE TO RUXOLITINIB — PRELIMINARY DATA FROM THE MANIFEST STUDY. (23rd June 2022) Authors: Mascarenhas, J.; Kremyanskaya, M.; Patriarca, A.; Harrison, C.; Bose, P.; Rampal, R. K.; Palandri, F; Devos, T.; Passamonti, F.; Hobbs, G.; Talpaz, M.; Vannucchi, A.; Kiladjian, J.-J.; Verstovsek, S.; Hoffman, R.; Salama, M. E.; Chen, D.; Taverna, P.; Chang, A.; Colak, G. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 99 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗